6-K

0001193125-21-324213.txt : 20211109 0001193125-21-324213.hdr.sgml : 20211109 20211109132155 ACCESSION NUMBER: 0001193125-21-324213 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20211109 FILED AS OF DATE: 20211109 DATE AS OF CHANGE: 20211109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYBIN INC. CENTRAL INDEX KEY: 0001833141 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40673 FILM NUMBER: 211391204 BUSINESS ADDRESS: STREET 1: 100 KING STREET WEST STREET 2: SUITE 5600 CITY: TORONTO STATE: A6 ZIP: M5X 1C9 BUSINESS PHONE: (908) 764-8385 MAIL ADDRESS: STREET 1: 100 KING STREET WEST STREET 2: SUITE 5600 CITY: TORONTO STATE: A6 ZIP: M5X 1C9 6-K 1 d257566d6k.htm 6-K 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2021.

Commission File Number: 001-40673

Cybin Inc.

(Exact Name of Registrant as Specified in Charter)

100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☐ Form 40-F ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	CYBIN INC.
	(Registrant)

Date: November 9, 2021	By:	/s/ Doug Drysdale
	Name:	Doug Drysdale
	Title:	Chief Executive Officer

EXHIBIT INDEX


99.1		News Release dated November 9, 2021

EX-99.1 2 d257566dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO

Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021

TORONTO, CANADA – November 9, 2021 – Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics^TM” today announced that it will report financial results for its second quarter of fiscal 2021 ended September 30, 2021 on Monday, November 15, 2021.

A conference call will be held on the same day at 4:30 p.m. (EST) to discuss the results and recent business updates. The call will be hosted by Doug Drysdale, Cybin’s Chief Executive Officer. Mr. Drysdale and other members of the management team will be available to answer questions from participants following the prepared remarks.

CONFERENCE CALL DETAILS:


DATE:		Monday, November 15, 2021

TIME:		4:30 p.m. (EST)

DIAL-IN		1-844-200-6205 (U.S. toll free) or 1-833-950-0062 (Canada toll free)

CODE		727873

WEBCAST		https://events.q4inc.com/attendee/747515026

An archived webcast will also be available on the Company’s Investor Relations site under the Events & Presentations page.

About Cybin

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Investor & Media Contacts:

Leah Gibson

Vice President, Investor Relations

Cybin Inc.

leah@cybin.com

Tim Regan/Scott Eckstein

KCSA Strategic Communications

cybin@kcsa.com

Lisa M. Wilson

In-Site Communications, Inc.

lwilson@insitecony.com

GRAPHIC 3 g257566g1109053229942.jpg GRAPHIC begin 644 g257566g1109053229942.jpg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